SLC19A1 rs3788205 — A Folate Transporter Haplotype Marker
SLC19A1 (Solute Carrier Family 19 Member 1), also known as the reduced folate carrier (RFC1), is the primary transporter that moves folate and antifolate drugs from the bloodstream into cells. rs3788205 is an intronic variant in the same gene — it does not alter the protein itself.
The Mechanism
As an intronic variant, rs3788205 does not directly change the SLC19A1 amino acid sequence. Intronic variants can theoretically influence gene expression through effects on splicing enhancers, regulatory elements, or transcription factor binding sites embedded within introns. However, no functional characterization of this specific site has been published to date. The T allele is the minor allele globally (~28% overall, ~30% in Europeans, only ~7% in Africans per dbSNP ALFA data).
The Evidence
The clearest direct finding comes from a
Phase III lung cancer trial11 Phase III lung cancer trial
Smit EF et al. Biomarker analysis of pemetrexed-carboplatin vs. etoposide-carboplatin in SCLC. Annals of Oncology, 2012,
which found that rs3788205 interacted with gamma-glutamyl hydrolase (GGH)-associated
SNPs to predict overall survival in patients receiving pemetrexed-carboplatin. This is
biologically plausible since pemetrexed, like methotrexate, depends on RFC1/SLC19A1
for cellular entry. An
Italian case-control study22 Italian case-control study
Girardi A et al. RFC1 and non-syndromic cleft lip/palate association study in Italy. J Craniomaxillofac Surg, 2014
examined rs3788205 alongside rs1051266 and rs4818789 in the context of cleft lip with
or without cleft palate, reporting weak association signals across the three RFC1
polymorphisms. A
Japanese autism spectrum disorder study33 Japanese autism spectrum disorder study
Mahmuda NA et al. SLC19A1/RFC1 SNPs in autism spectrum disorder. Int J Mol Sci, 2016
included rs3788205 in a 13-SNP SLC19A1 panel but found no significant association
after correction for multiple testing. rs3788205 is not among the five SLC19A1
tagSNPs that reached corrected significance in the colorectal adenoma study
Levine AJ et al., 201144 Levine AJ et al., 2011
Cancer Causes Control, folate pathway variation and distal colorectal adenoma.
Taken together, the evidence for this variant as an independent risk factor is weak. The evidence level is emerging — the variant appears across folate-pathway studies but has not been replicated with a clear, directional effect in any single phenotype.
Practical Context
The practical implications are best understood in the context of your other folate pathway results, especially rs1051266 (the G80A missense variant in the same gene) and MTHFR variants.
The most actionable approach for anyone with T-allele status at this locus is to ensure optimal folate intake and to use methylfolate rather than synthetic folic acid — advice consistent with the broader SLC19A1 pathway evidence.
Interactions
rs3788205 is in the same gene as rs1051266 (G80A, His27Arg), the primary functional variant in SLC19A1.